{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T17:13:56Z","timestamp":1779124436557,"version":"3.51.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100013955","name":"Astellas Pharma, Netherlands","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40262-026-01640-6","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T11:52:07Z","timestamp":1777895527000},"page":"763-772","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of Enzalutamide on Morphine Exposure in Patients with Prostate Cancer"],"prefix":"10.1007","volume":"65","clinical-trial-number":[{"clinical-trial-number":"nct05339672","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4204-5346","authenticated-orcid":false,"given":"Catharina J. P.","family":"Op \u2018t Hoog","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niven","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benthe","family":"van der Weij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Olofsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diederik M.","family":"Somford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inge M.","family":"van Oort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Hamberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1553-178X","authenticated-orcid":false,"given":"Nielka P.","family":"van Erp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmy","family":"Boerrigter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"1640_CR1","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Public assessment report enzalutamide. European Medicines Agency (EMA). 2013 and updates. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xtandi. Accessed 16 Jul 2026."},{"issue":"5","key":"1640_CR2","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424\u201333.","journal-title":"N Engl J Med"},{"issue":"26","key":"1640_CR3","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","volume":"378","author":"M Hussain","year":"2018","unstructured":"Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378(26):2465\u201374.","journal-title":"N Engl J Med"},{"issue":"13","key":"1640_CR4","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin M-E, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187\u201397.","journal-title":"N Engl J Med"},{"issue":"32","key":"1640_CR5","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37(32):2974\u201386.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1640_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2):121\u201331.","journal-title":"N Engl J Med"},{"issue":"1","key":"1640_CR7","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/bcp.13425","volume":"84","author":"GE Benoist","year":"2018","unstructured":"Benoist GE, van Oort IM, Smeenk S, Javad A, Somford DM, Burger DM, et al. Drug-drug interaction potential in men treated with enzalutamide: mind the gap. Br J Clin Pharmacol. 2018;84(1):122\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"1640_CR8","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s40262-015-0283-1","volume":"54","author":"JA Gibbons","year":"2015","unstructured":"Gibbons JA, de Vries M, Krauwinkel W, Ohtsu Y, Noukens J, van der Walt JS, et al. Pharmacokinetic drug interaction studies with enzalutamide. Clin Pharmacokinet. 2015;54(10):1057\u201369.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1640_CR9","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1111\/cts.13229","volume":"15","author":"S Poondru","year":"2022","unstructured":"Poondru S, Ghicavii V, Khosravan R, Manchandani P, Heo N, Moy S, et al. Effect of enzalutamide on PK of P-gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters. Clin Transl Sci. 2022;15(5):1131\u2013222.","journal-title":"Clin Transl Sci"},{"issue":"3","key":"1640_CR10","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.ejpain.2007.07.006","volume":"12","author":"HJ Gerbershagen","year":"2008","unstructured":"Gerbershagen HJ, Ozgur E, Straub K, Dagtekin O, Gerbershagen K, Petzke F, et al. Prevalence, severity, and chronicity of pain and general health-related quality of life in patients with localized prostate cancer. Eur J Pain. 2008;12(3):339\u201350.","journal-title":"Eur J Pain"},{"issue":"1","key":"1640_CR11","first-page":"28","volume":"31","author":"EA Walsh","year":"2022","unstructured":"Walsh EA, Pedreira PB, Moreno PI, Popok PJ, Fox RS, Yanez B, et al. Pain, cancer-related distress, and physical and functional well-being among men with advanced prostate cancer. Support Care Cancer. 2022;31(1):28.","journal-title":"Support Care Cancer"},{"issue":"9784","key":"1640_CR12","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1016\/S0140-6736(11)60236-5","volume":"377","author":"RK Portenoy","year":"2011","unstructured":"Portenoy RK. Treatment of cancer pain. Lancet. 2011;377(9784):2236\u201347.","journal-title":"Lancet"},{"issue":"Suppl. 4","key":"1640_CR13","doi-asserted-by":"publisher","first-page":"iv166","DOI":"10.1093\/annonc\/mdy152","volume":"29","author":"M Fallon","year":"2018","unstructured":"Fallon M, Giusti R, Aielli F, Hoskin P, Rolke R, Sharma M, et al. Management of cancer pain in adult patients: ESMO clinical practice guidelines. Ann Oncol. 2018;29(Suppl. 4):iv166\u201391.","journal-title":"Ann Oncol"},{"issue":"2","key":"1640_CR14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.eururo.2018.09.011","volume":"75","author":"GE Benoist","year":"2019","unstructured":"Benoist GE, van Oort IM, Burger DM, Koch BCP, Mehra N, van Erp NP. The combination of enzalutamide and opioids: a painful pitfall? Eur Urol. 2019;75(2):351\u20132.","journal-title":"Eur Urol"},{"issue":"7","key":"1640_CR15","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s40262-023-01255-1","volume":"62","author":"SEH Detert Oude Weme","year":"2023","unstructured":"Detert Oude Weme SEH, Hulskotte LMG, Vervenne WL, Imholz ALT, Cremers R, Taxis K, et al. Enzalutamide reduces oxycodone exposure in men with prostate cancer. Clin Pharmacokinet. 2023;62(7):989\u201396.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1640_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11011-011-9274-6","volume":"27","author":"S De Gregori","year":"2012","unstructured":"De Gregori S, De Gregori M, Ranzani GN, Allegri M, Minella C, Regazzi M. Morphine metabolism, transport and brain disposition. Metab Brain Dis. 2012;27(1):1\u20135.","journal-title":"Metab Brain Dis"},{"issue":"4","key":"1640_CR17","doi-asserted-by":"publisher","first-page":"344","DOI":"10.2165\/00003088-199324040-00007","volume":"24","author":"J Hasselstr\u00f6m","year":"1993","unstructured":"Hasselstr\u00f6m J, S\u00e4we J. Morphine pharmacokinetics and metabolism in humans. Clin Pharmacokinet. 1993;24(4):344\u201354.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"1640_CR18","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1093\/bja\/aeu186","volume":"113","author":"R Klimas","year":"2014","unstructured":"Klimas R, Mikus G. Morphine-6-glucuronide is responsible for the analgesic effect after morphine administration: a quantitative review of morphine, morphine-6-glucuronide, and morphine-3-glucuronide. Br J Anaesth. 2014;113(6):935\u201344.","journal-title":"Br J Anaesth"},{"issue":"5","key":"1640_CR19","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/med.20035","volume":"25","author":"GJ Kilpatrick","year":"2005","unstructured":"Kilpatrick GJ, Smith TW. Morphine-6-glucuronide: actions and mechanisms. Med Res Rev. 2005;25(5):521\u201344.","journal-title":"Med Res Rev"},{"issue":"9","key":"1640_CR20","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1124\/dmd.31.9.1086","volume":"31","author":"AN Stone","year":"2003","unstructured":"Stone AN, Mackenzie PI, Galetin A, Houston JB, Miners JO. Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human UDP-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. Drug Metab Dispos. 2003;31(9):1086\u20139.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"1640_CR21","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1124\/dmd.107.019281","volume":"36","author":"S Ohno","year":"2008","unstructured":"Ohno S, Kawana K, Nakajin S. Contribution of UDP-glucuronosyltransferase 1A1 and 1A8 to morphine-6-glucuronidation and its kinetic properties. Drug Metab Dispos. 2008;36(4):688\u201394.","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"1640_CR22","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S0090-9556(25)09039-7","volume":"19","author":"JT Van Crugten","year":"1991","unstructured":"Van Crugten JT, Sallustio BC, Nation RL, Somogyi AA. Renal tubular transport of morphine, morphine-6-glucuronide, and morphine-3-glucuronide in the isolated perfused rat kidney. Drug Metab Dispos. 1991;19(6):1087\u201392.","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"1640_CR23","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s002280050003","volume":"55","author":"P Klepstad","year":"2000","unstructured":"Klepstad P, Kaasa S, Borchgrevink PC. Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine. Eur J Clin Pharmacol. 2000;55(10):713\u20139.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"1640_CR24","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.ejpain.2010.09.007","volume":"15","author":"AR Binning","year":"2011","unstructured":"Binning AR, Przesmycki K, Sowinski P, Morrison LM, Smith TW, Marcus P, et al. A randomised controlled trial on the efficacy and side-effect profile (nausea\/vomiting\/sedation) of morphine-6-glucuronide versus morphine for post-operative pain relief after major abdominal surgery. Eur J Pain. 2011;15(4):402\u20138.","journal-title":"Eur J Pain"},{"issue":"13","key":"1640_CR25","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.addr.2010.08.006","volume":"62","author":"AH Tolson","year":"2010","unstructured":"Tolson AH, Wang H. Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR. Adv Drug Deliv Rev. 2010;62(13):1238\u201349.","journal-title":"Adv Drug Deliv Rev"},{"issue":"9","key":"1640_CR26","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/bdd.2103","volume":"38","author":"J Weiss","year":"2017","unstructured":"Weiss J, Kocher J, Mueller C, Rosenzweig S, Theile D. Impact of enzalutamide and its main metabolite N-desmethyl enzalutamide on pharmacokinetically important drug metabolizing enzymes and drug transporters. Biopharm Drug Dispos. 2017;38(9):517\u201325.","journal-title":"Biopharm Drug Dispos"},{"key":"1640_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2025.111829","volume":"423","author":"T Zheng","year":"2026","unstructured":"Zheng T, Yin H, Shan H, Sun L, Jiang L, Liu Y. Synergistic inhibitory effects of enzalutamide and its phase I metabolite on UDP-glucuronosyltransferase 1A1 (UGT1A1) and risk prediction of drug-drug interactions. Chem Biol Interact. 2026;423:111829.","journal-title":"Chem Biol Interact"},{"key":"1640_CR28","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Guideline on bioanalytical method validation. European Medicines Agency (EMA). 2023. Available from: https:\/\/www.ema.europa.eu\/en\/ich-m10-bioanalytical-method-validation-scientific-guideline. Accessed 3 Mar 2026."},{"issue":"2","key":"1640_CR29","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1097\/FTD.0000000000000484","volume":"40","author":"GE Benoist","year":"2018","unstructured":"Benoist GE, van der Meulen E, van Oort IM, Beumer JH, Somford DM, Schalken JA, et al. Development and validation of a bioanalytical method to quantitate enzalutamide and its active metabolite N-desmethylenzalutamide in human plasma: application to clinical management of patients with metastatic castration-resistant prostate cancer. Ther Drug Monit. 2018;40(2):222\u20139.","journal-title":"Ther Drug Monit"},{"issue":"3","key":"1640_CR30","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0885-3924(99)00068-8","volume":"18","author":"LL Christrup","year":"1999","unstructured":"Christrup LL, Sjogren P, Jensen NH, Banning AM, Elbaek K, Ersboll AK. Steady-state kinetics and dynamics of morphine in cancer patients: is sedation related to the absorption rate of morphine? J Pain Symptom Manage. 1999;18(3):164\u201373.","journal-title":"J Pain Symptom Manage"},{"key":"1640_CR31","unstructured":"Shargel L, Ducharme MP. Shargel and Yu's Applied biopharmaceutics and pharmacokinetics. 8th ed. McGraw Hill Education, New York, United States of America; 2022."},{"key":"1640_CR32","unstructured":"Committee for Medicinal Products for Human Use (CHMP). ICH M13A Guideline on bioequivalence for immediate-release solid oral dosage forms. 2025. Available from: https:\/\/www.ema.europa.eu\/en\/ich-guideline-m13a-bioequivalence-immediate-release-solid-oral-dosage-forms-scientific-guideline. Accessed 25 Jul 2026."},{"key":"1640_CR33","unstructured":"U.S. Department of Health and Human Services. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017. Available from: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events. Accessed 20 July 2025"},{"key":"1640_CR34","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Guideline on the investigation of bioequivalence. European Medicines Agency (EMA). 2010. Available from: https:\/\/www.ema.europa.eu\/en\/investigation-bioequivalence-scientific-guideline. Accessed 25 Jul 2026."},{"key":"1640_CR35","unstructured":"Center for Drug Evaluation and Research. Statistical approaches to establishing bioequivalence. US Food and Drug Administration (FDA). 2001. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/statistical-approaches-establishing-bioequivalence. Accessed 25 Jul 2026."},{"key":"1640_CR36","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1472-6904-4-7","volume":"4","author":"P Klepstad","year":"2004","unstructured":"Klepstad P, Hilton P, Moen J, Kaasa S, Borchgrevink PC, Zahlsen K, et al. Day-to-day variations during clinical drug monitoring of morphine, morphine-3-glucuronide and morphine-6-glucuronide serum concentrations in cancer patients: a prospective observational study. BMC Clin Pharmacol. 2004;4:7.","journal-title":"BMC Clin Pharmacol"},{"issue":"7","key":"1640_CR37","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/0885-3924(91)90042-3","volume":"6","author":"GK Gourlay","year":"1991","unstructured":"Gourlay GK, Plummer JL, Cherry DA, Purser T. The reproducibility of bioavailability of oral morphine from solution under fed and fasted conditions. J Pain Symptom Manage. 1991;6(7):431\u20136.","journal-title":"J Pain Symptom Manage"},{"issue":"3","key":"1640_CR38","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1081\/BIP-120022772","volume":"13","author":"P Zhang","year":"2003","unstructured":"Zhang P. A simple formula for sample size calculation in equivalence studies. J Biopharm Stat. 2003;13(3):529\u201338.","journal-title":"J Biopharm Stat"},{"key":"1640_CR39","unstructured":"Sanofi-Aventis. Rifampin (Rifadin). Summary of Product Characteristics. 2025."},{"issue":"1\u20132","key":"1640_CR40","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S0304-3959(97)00044-4","volume":"72","author":"MF Fromm","year":"1997","unstructured":"Fromm MF, Eckhardt K, Li S, Sch\u00e4nzle G, Hofmann U, Mikus G, et al. Loss of analgesic effect of morphine due to coadministration of rifampin. Pain. 1997;72(1\u20132):261\u20137.","journal-title":"Pain"},{"issue":"6","key":"1640_CR41","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s40262-020-00867-1","volume":"59","author":"M Elmeliegy","year":"2020","unstructured":"Elmeliegy M, Vourvahis M, Guo C, Wang DD. Effect of P-glycoprotein (P-gp) inducers on exposure of P-gp substrates: review of clinical drug-drug interaction studies. Clin Pharmacokinet. 2020;59(6):699\u2013714.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1640_CR42","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1093\/bja\/70.5.511","volume":"70","author":"MH Hanna","year":"1993","unstructured":"Hanna MH, D\u2019Costa F, Peat SJ, Fung C, Venkat N, Zilkha TR, et al. Morphine-6-glucuronide disposition in renal impairment. Br J Anaesth. 1993;70(5):511\u20134.","journal-title":"Br J Anaesth"},{"issue":"1","key":"1640_CR43","doi-asserted-by":"publisher","first-page":"21356","DOI":"10.1038\/s41598-021-00338-y","volume":"11","author":"T Imaoka","year":"2021","unstructured":"Imaoka T, Huang W, Shum S, Hailey DW, Chang SY, Chapron A, et al. Bridging the gap between in silico and in vivo by modeling opioid disposition in a kidney proximal tubule microphysiological system. Sci Rep. 2021;11(1):21356.","journal-title":"Sci Rep"},{"key":"1640_CR44","unstructured":"Wu D, Kang Y-S, Bickel U, Pardridge WM. Blood-Brain Barrier Permeability to Morphine-6-Glucuronide is Markedly Reduced Compared with Morphine. Drug Metab Dispos. 1997;25(6):768\u201371."},{"issue":"1","key":"1640_CR45","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0022-3565(25)20113-6","volume":"278","author":"U Bickel","year":"1996","unstructured":"Bickel U, Schumacher OP, Kang YS, Voigt K. Poor permeability of morphine 3-glucuronide and morphine 6-glucuronide through the blood-brain barrier in the rat. J Pharmacol Exp Ther. 1996;278(1):107\u201313.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1 Pt 2","key":"1640_CR46","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/j.1399-6576.1997.tb04625.x","volume":"41","author":"LL Christrup","year":"1997","unstructured":"Christrup LL. Morphine metabolites. Acta Anaesthesiol Scand. 1997;41(1 Pt 2):116\u201322.","journal-title":"Acta Anaesthesiol Scand"},{"issue":"3","key":"1640_CR47","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ejpain.2008.04.015","volume":"13","author":"TW Smith","year":"2009","unstructured":"Smith TW, Binning AR, Dahan A. Efficacy and safety of morphine-6-glucuronide (M6G) for postoperative pain relief: a randomized, double-blind study. Eur J Pain. 2009;13(3):293\u20139.","journal-title":"Eur J Pain"},{"issue":"4","key":"1640_CR48","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/BF00543973","volume":"32","author":"J S\u00e4we","year":"1987","unstructured":"S\u00e4we J, Odar-Cederl\u00f6f I. Kinetics of morphine in patients with renal failure. Eur J Clin Pharmacol. 1987;32(4):377\u201382.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"1640_CR49","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/clpt.1993.127","volume":"54","author":"R Osborne","year":"1993","unstructured":"Osborne R, Joel S, Grebenik K, Trew D, Slevin M. The pharmacokinetics of morphine and morphine glucuronides in kidney failure. Clin Pharmacol Ther. 1993;54(2):158\u201367.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1640_CR50","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s00280-020-04039-7","volume":"85","author":"GE Benoist","year":"2020","unstructured":"Benoist GE, van Oort IM, Burger DM, Mehra N, van Erp NP. The impact of patient characteristics on enzalutamide pharmacokinetics and how this relates to treatment toxicity and efficacy in metastatic prostate cancer patients. Cancer Chemother Pharmacol. 2020;85(4):753\u201360.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"1640_CR51","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/hup.2394","volume":"29","author":"B Setnik","year":"2014","unstructured":"Setnik B, Sokolowska M, Johnson F, Oldenhof J, Romach M. Evaluation of the safety, pharmacodynamic, and pharmacokinetic effects following oral coadministration of immediate-release morphine with ethanol in healthy male participants. Hum Psychopharmacol. 2014;29(3):251\u201365.","journal-title":"Hum Psychopharmacol"},{"issue":"1","key":"1640_CR52","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jpainsymman.2004.04.015","volume":"29","author":"NA Hagen","year":"2005","unstructured":"Hagen NA, Thirlwell M, Eisenhoffer J, Quigley P, Harsanyi Z, Darke A. Efficacy, safety, and steady-state pharmacokinetics of once-a-day controlled-release morphine (MS Contin XL) in cancer pain. J Pain Symptom Manage. 2005;29(1):80\u201390.","journal-title":"J Pain Symptom Manage"},{"issue":"4","key":"1640_CR53","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/S0885-3924(02)00382-2","volume":"23","author":"RK Portenoy","year":"2002","unstructured":"Portenoy RK, Sciberras A, Eliot L, Loewen G, Butler J, Devane J. Steady-state pharmacokinetic comparison of a new, extended-release, once-daily morphine formulation, Avinza, and a twice-daily controlled-release morphine formulation in patients with chronic moderate-to-severe pain. J Pain Symptom Manage. 2002;23(4):292\u2013300.","journal-title":"J Pain Symptom Manage"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01640-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01640-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01640-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T17:01:55Z","timestamp":1779123715000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01640-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1640"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01640-6","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"15 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Niven Mehra received consultancy fees from Janssen-Cilag, Bayer, Astellas Pharma, AstraZeneca, Pfizer, and MSD and research funding form Janssen-Cilag, Astellas Pharma, AstraZeneca\/Merck, and Bristol Myers Squibb Foundation (all paid to the institute). Diederik M. Somford received consultancy and\/or speaker fees from ABX, Accord Healthcare, Blue Earth Diagnostics, Bayer, Ipsen, Janssen, and Mayumana; travel expenses from Bayer and Pfizer; and research funding from AstraZeneca, Bayer, Besins, Blue Earth Diagnostics, Eli Lilly, Ipsen, Janssen, Novartis, and Pfizer (all paid to the institute). Inge M. van Oort received consultancy fees from Bayer, AstraZeneca, Novartis, and MSD and received research funding from Astellas Pharma, Bayer, AstraZeneca, Novartis, and MSD (all paid to the institute). Paul Hamberg received consultancy fees from Astellas Pharma, MSD, Pfizer AstraZeneca, BMS, and Ipsen (all paid to the institute). Nielka P. van Erp has received research funding from Astellas Pharma (all paid to the institute). Catharina J.P. Op \u2018t Hoog, Benthe van der Weij, Erik Olofsen, and Emmy Boerrigter have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/Competing interests"}},{"value":"The study was approved by the local Medical Research Ethics Committee Oost-Nederland (Nijmegen, the Netherlands) and conducted in accordance with Good Clinical Practice and the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All patients provided written informed consent prior to participating in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All patients provided written informed consent for publication of the results.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data are available on reasonable request from the authors.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"NPvE, EB, NM, DMS, IMvO, and PH developed the concept and design of the study. NM, DSM, IMvO, and CJPOtH were responsible for patient recruitment and data acquisition. CJPOtH and BvdW were responsible for data analysis, statistical analysis, and interpretation, supervised by EB and NPvE. CJPOtH and BvdW prepared the manuscript. EB, NPvE, NM, DMS, IMvO, EO, and PH were responsible for critical reviewing the manuscript. All authors gave final approval of the version to be submitted.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}